Clinical trials: Brief Psychotic Disorder
Parent-Child Relations, Parenting
Examine the Feasibility and Acceptability of Project Support
In this study, the investigators will conduct a proof-of-concept pilot trial of delivering the Project Support Positive Parenting Module (Project Support) to n = 30 families waiting for trauma-focused services.
- Conditions
- Parent-Child Relations, Parenting, Child Mental Disorder
- Trial name
- NCT06391229
- Testing
- Project Support
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical University of South Carolina
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life
Purpose: To develop and test the feasibility of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring, and determine the effectiveness of this intervention on the physical and mental…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorder
- Trial name
- PACE-life (NCT03757988)
- Testing
- Exercise Intervention- PACE-Life
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
Brief Group Psychoeducation for Schizophrenia
This study evaluates the addition of psychoeducation to treatment as usual in the treatment of adults with schizophrenia for relapse prevention.
- Trial name
- NCT02911519
- Testing
- Brief Group Psychoeducation, Treatment as Usual
- Volunteers
- 176 people
- Sponsor
- Salud Mental Integral S.A.S.
Schizophrenia
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17…
- Trial name
- NCT01942161
- Testing
- Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day), Aripiprazole High (24 - 30 mg/day)
- Where
- 8 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
Targeting Physical Health in Schizophrenia: Physical Activity Can Enhance Life Randomized Control Trial
Purpose: To test the effectiveness of an exercise intervention that combines group walking, activity tracking, and heart rate monitoring (i.e.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Brief Psychotic Disorder, Schizophreniform Disorders
- Trial name
- (PACE-life (NCT04173572)
- Testing
- PACE-Life, Exercise Intervention
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of North Carolina, Chapel Hill
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia, Schizoaffective Disorder
An Integrated Program for the Treatment of First Episode of Psychosis
The purpose of this study is to determine how services should be provided to reduce symptoms and improve life functioning for adolescents and adults who have been recently diagnosed with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Brief Psychotic Disorder
- Trial name
- RAISE ETP (NCT01321177)
- Testing
- Integrated Treatment, Community Care
- Where
- 33 sites in United States
- Volunteers
- 404 people
- Sponsor
- Northwell Health
Schizophrenia, Psychotic Disorders
A Brief Community Linkage Intervention for Dually Diagnosed Individuals
Surveys suggest that up to 80% of veterans with a persistent mental illness have a co-occurring substance use disorder. Substance abuse among this population is problematic and often results in poor engagement in treatment and…
- Conditions
- Schizophrenia, Psychotic Disorders, Substance-Related Disorders, Bipolar Disorder
- Trial name
- TLC (NCT00137267)
- Testing
- Time limited case management, Health Education
- Where
- 2 sites in United States
- Volunteers
- 102 people
- Sponsor
- US Department of Veterans Affairs
Psychosis
Testing the Effectiveness of The Welcome Basket Intervention
The investigators propose to examine the effectiveness of a brief intervention that might better facilitate the transition into the community for people with schizophrenia or bipolar disorder with psychotic features.
- Trial name
- NCT02946255
- Testing
- Welcome Basket (WB), Welcome Basket Brief (WBbr), Treatment As Usual
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia
A Physical Dependence Study in Schizophrenia
The purpose of this study is to determine whether or not people with schizophrenia who take LY2140023 become physically dependent on it, and experience a series of symptoms such as craving to have the drug when they stop using…
- Trial name
- NCT01452919
- Testing
- LY2140023
- Where
- 10 sites in United States, Greece
- Volunteers
- 123 people
- Sponsor
- Denovo Biopharma LLC
NMDA Receptor Function
The Effects of Ketamine and Guanfacine on Working Memory in Healthy Subjects
The purpose of the study is 1. To establish the feasibility of fMRI studies of the interaction of guanfacine and ketamine. 2. To explore the possibility that guanfacine can ameliorate the negative effects of ketamine on…
- Trial name
- GuaKet (NCT01600885)
- Testing
- Guanfacine
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Yale University
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia
This is a randomized, double-blind, active-controlled, 6 month study designed to evaluate the cognitive effects of treatment with CYP-1020 compared to risperidone.
- Trial name
- CLARITY (NCT01363349)
- Testing
- CYP-1020, Risperidone
- Where
- 39 sites in India, Moldova and 1 more
- Volunteers
- 269 people
- Sponsor
- BioLineRx, Ltd.
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.